Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication
作者:Maria Letizia Barreca、Giuseppe Manfroni、Pieter Leyssen、Johan Winquist、Neerja Kaushik-Basu、Jan Paeshuyse、Ramalingam Krishnan、Nunzio Iraci、Stefano Sabatini、Oriana Tabarrini、Amartya Basu、U. Helena Danielson、Johan Neyts、Violetta Cecchetti
DOI:10.1021/jm301643a
日期:2013.3.28
The NS5B RNA-dependent RNA polymerase is an attractive target for the development of novel and selective inhibitors of hepatitis C virus replication. To identify novel structural hits as anti-HCV agents, we performed structure-based virtual screening of our in-house library followed by rational drug design, organic synthesis, and biological testing. These studies led to the identification of pyrazolobenzothiazine
NS5B RNA 依赖性 RNA 聚合酶是开发新型和选择性丙型肝炎病毒复制抑制剂的有吸引力的目标。为了确定新的结构命中作为抗 HCV 药物,我们对我们的内部库进行了基于结构的虚拟筛选,然后进行合理的药物设计、有机合成和生物测试。这些研究导致吡唑并苯并噻嗪支架被鉴定为获得靶向 NS5B 聚合酶的新型抗 HCV 药物的合适模板。该系列中最好的化合物是间-氟-N - 1-苯基吡唑并苯并噻嗪衍生物4a,其 EC 50 = 3.6 μM、EC 90 = 25.6 μM 和 CC 50 在 Huh 9-13 复制子系统中 > 180 μM,从而为进一步的命中进化提供了良好的起点。